In this study, we investigate how TGFβ in conjunction with cytotoxic therapy suppresses anti-tumor immunity through the use of clinical ALK5 small molecule inhibitors and cell-type conditional ALK5-deficient mice. Here, TGFBR1 is linked to neoplasm.